Last reviewed · How we verify
Losartan and hydrochlorothiazide
At a glance
| Generic name | Losartan and hydrochlorothiazide |
|---|---|
| Sponsor | University of Cambridge |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension (PHASE2)
- Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients (PHASE4)
- Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension (PHASE3)
- Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322) (PHASE3)
- MK0954A-264 Filter Study (0954A-264)(COMPLETED) (PHASE3)
- HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED) (PHASE3)
- Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323) (PHASE3)
- Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Losartan and hydrochlorothiazide CI brief — competitive landscape report
- Losartan and hydrochlorothiazide updates RSS · CI watch RSS
- University of Cambridge portfolio CI